FDA replaces Women’s Health director

Share this article:
The FDA named Theresa Toigo acting director of its Office of Women's Health (OWH).
She replaces Susan Wood, who quit this month in protest after the agency refused to permit OTC sales of Barr's Plan B emergency contraceptive.
Toigo is an FDA veteran who also heads the agency's Office of Special Health Issues.
The FDA will conduct a search for a permanent replacement, an FDA spokeswoman told MM&M, although a timeframe for finding a permanent OWH director is not being given.
Dr. Lester Crawford, FDA commissioner, announced Toigo's appointment Friday.
Crawford's own confirmation had been held up by Senate Democrats until the administration set a Sept. 1 deadline for FDA to make a decision on Plan B. On Aug. 26, however, Crawford ordered a 60-day public comment period on Plan B, saying the regulatory and policy issues raised by Barr's application -- i.e., whether Plan B can switch to OTC status for women ages 16 and older and remain Rx status for women under 16 -- were too weighty to be decided behind closed doors.
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.